Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Liabilities from Discontinued Operations (2025)

Adma Biologics (ADMA) has disclosed Liabilities from Discontinued Operations for 1 consecutive years, with 2647000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Liabilities from Discontinued Operations changed N/A year-over-year to 2647000.0, compared with a TTM value of 2647000.0 through Dec 2025, changed N/A, and an annual FY2025 reading of 2647000.0, changed N/A over the prior year.
  • Liabilities from Discontinued Operations was 2647000.0 for Q4 2025 at Adma Biologics.
  • Across five years, Liabilities from Discontinued Operations topped out at 2647000.0 in Q4 2025 and bottomed at 2647000.0 in Q4 2025.